- Home
- LCTX vs TBRG Comparison
LCTX vs TBRG Comparison
Compare LCTX & TBRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- TBRG
- Stock Information
- Founded
- LCTX 1990
- TBRG 1979
- Country
- LCTX United States
- TBRG United States
- Employees
- LCTX N/A
- TBRG N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- TBRG
- Sector
- LCTX Health Care
- TBRG
- Exchange
- LCTX Nasdaq
- TBRG NYSE
- Market Cap
- LCTX 165.6M
- TBRG 186.6M
- IPO Year
- LCTX N/A
- TBRG N/A
- Fundamental
- Price
- LCTX $0.89
- TBRG $12.35
- Analyst Decision
- LCTX Strong Buy
- TBRG Buy
- Analyst Count
- LCTX 3
- TBRG 2
- Target Price
- LCTX $5.67
- TBRG $13.50
- AVG Volume (30 Days)
- LCTX 327.9K
- TBRG 57.4K
- Earning Date
- LCTX 11-07-2024
- TBRG 11-06-2024
- Dividend Yield
- LCTX N/A
- TBRG N/A
- EPS Growth
- LCTX N/A
- TBRG N/A
- EPS
- LCTX N/A
- TBRG N/A
- Revenue
- LCTX $6,186,000.00
- TBRG $336,557,000.00
- Revenue This Year
- LCTX N/A
- TBRG $0.94
- Revenue Next Year
- LCTX $119.00
- TBRG $4.58
- P/E Ratio
- LCTX N/A
- TBRG N/A
- Revenue Growth
- LCTX N/A
- TBRG N/A
- 52 Week Low
- LCTX $0.77
- TBRG $7.55
- 52 Week High
- LCTX $1.61
- TBRG $17.28
- Technical
- Relative Strength Index (RSI)
- LCTX 48.24
- TBRG 48.70
- Support Level
- LCTX $0.83
- TBRG $11.77
- Resistance Level
- LCTX $0.94
- TBRG $12.84
- Average True Range (ATR)
- LCTX 0.05
- TBRG 0.40
- MACD
- LCTX 0.00
- TBRG -0.10
- Stochastic Oscillator
- LCTX 41.92
- TBRG 20.54
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About TBRG TRUBRIDGE INC
TruBridge Inc is a provider of healthcare solutions and services for community hospitals, clinics, and other healthcare systems. It provides services such as Electronic health records & information systems, revenue cycle management, population health, and data management, etc. The segments of the company are RCM, EHR, and Patient Engagement. The company derives maximum revenue from the RCM segment.